Skip to content
Kalpvruksh Markets
Offline Log in

MOLBIONSEOffline

Molbio Diagnostics · INE869T01028
1,403.50+21.70 (+1.57%)last close · 05 Nov 2026
Prev close
1,381.80
Open
—
High
—
Low
—
Volume
—
Mkt cap (6-mo avg)
—

Loading minute bars…

NSE 1-minute bars from our CandleApi gateway (history from 21 Jul 2026); longer timeframes are built from them. Prices not adjusted for corporate actions.

Overview

What the data says, line by line

A description, never a buy or sell word · tap a line for its detail

  • MF schemes in Sept 2026: 4 bought, 10 cut · no promoter pledge
  • nothing scheduled or restricting

Did buyers take delivery?

latest session · 2026-11-05

vs its own normal
0.6×
median 1,59,927
Delivered
95,834
Of volume
25%

Price & trend

Price & trend

Not enough price historyFigures need 60 sessions of NSE prices.

Ownership

Who owns the company

% of all shares, by quarter

GroupSep 26
Promoters41.3%
FPI1.6%
Mutual funds8.0%
Other DII11.1%
Individuals25.0%
Others13.0%

From the company’s quarterly shareholding pattern. Changes in percentage points against the quarter before. No quarters are on record between Sep 2022 and Jun 2025.

Promoter pledge

Sep 26

Of promoters’ holding
none
Of all shares
none
Sep 26 none

Holders

Sep 26

All shareholders
50,395
Individuals
48,681

Which funds bought and sold

No fund holds this companyNo Indian mutual fund disclosed a position at the last quarter end.

Mutual-fund schemes, month by month

fund houses’ own monthly portfolios

MonthSchemesBought newAddedCutSold outShares heldValue
Sep 26203182+57.3%₹716 cr
Aug 261919000—₹378 cr

Each month against the one before, counting only the fund houses that reported both (45 houses in Sep 26); a split or bonus is divided out first. “Partial” = fewer than five houses reported yet.

Fund ownership is a quarterly disclosure and counts Indian passive schemes only.

Results

Results

Events & filings

Disclosures & deals

last six months · NSE filings

  • Board outcome
    Molbio Diagnostics Limited has informed the Exchange regarding Outcome of Board Meeting held on September 25, 2026 for re-appointment of M/s K. S. Kamalakara & Co, Cost Accountants as the Cost Auditor of the Company for FY 2026-27.
    25 Sept 2026
  • Board outcome
    Molbio Diagnostics Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
    07 Sept 2026
  • Board outcome
    Molbio Diagnostics Limited has informed the Exchange regarding Outcome of Board Meeting held on August 27, 2026.
    28 Aug 2026
  • Bulk deal: BUY
    5,90,709 at ₹1,288.14 — JUNOMONETA FINSOL PRIVATE LIMITED
    16 Sept 2026
  • Bulk deal: SELL
    5,91,823 at ₹1,288.6 — JUNOMONETA FINSOL PRIVATE LIMITED
    16 Sept 2026
  • Bulk deal: SELL
    6,01,018 at ₹1,547.45 — HRTI PRIVATE LIMITED
    11 Sept 2026
  • Bulk deal: BUY
    7,37,245 at ₹1,520.67 — HRTI PRIVATE LIMITED
    11 Sept 2026

Latest shown; 8 in six months on all disclosures.

MOLBIO: only ratings, pledges, insider and takeover disclosures, buybacks, schemes, board outcomes and deals are listed. All deals.

Market capitalisation is our own six-month average, computed the way AMFI computes it; the published classification is on the market cap page. Fund ownership is a quarterly disclosure and counts Indian passive schemes only. Nothing here is advice, a recommendation, or a view on the company.